帕妥珠单抗联合曲妥珠单抗、多西他赛一线治疗HER2阳性转移性乳腺癌的成本-效用分析
2022-03-04贾才凤张森徐浩李赛男王明霞
贾才凤 张森 徐浩 李赛男 王明霞








中图分类号 R737.9;R956 文献标志码 A 文章编号 1001-0408(2022)04-0481-06
DOI 10.6039/j.issn.1001-0408.2022.04.16
摘 要 目的 评价帕妥珠单抗联合曲妥珠单抗、多西他赛(PTD)方案相比曲妥珠单抗联合多西他赛(TD)方案一线治疗人表皮生长因子受体2(HER2)阳性转移性乳腺癌的经济性。方法 从我国卫生体系角度出发,利用CLEOPATRA临床试验披露的生存数据和相关文献数据构建分区生存模型,模型模拟时限设为20年,循环周期为3周,贴现率为5%。模型的产出指标包括两种治疗方案的成本及质量调整生命年(QALYs)。意愿支付(WTP)阈值设为2020年我国1~3倍人均国内生产总值(GDP),即72 000~216 000元/QALY。采用单因素敏感性分析及概率敏感性分析评价模型参数变化对结果稳健性的影响。结果 基础分析结果显示,在20年的模拟时限内,PTD方案较TD方案可带来更高的健康获益(3.28 QALYs vs. 2.50 QALYs),但总成本更高(1 219 376.83元 vs. 784 007.84元);与TD方案相比,PTD方案的增量成本-效果比为554 625.46元/QALY,超过WTP阈值。单因素敏感性分析结果显示,疾病无进展生存状态的效用值对结果的影响最大。概率敏感性分析结果显示,使用我国2020年3倍人均GDP作为WTP阈值时,PTD方案具有经济性的概率为1%;当WTP阈值升至550 000元/QALY时,PTD方案具有經济性的概率可达50%。结论 与TD方案相比,PTD方案一线治疗HER2阳性转移性乳腺癌不具有经济性。
关键词 帕妥珠单抗;曲妥珠单抗;多西他赛;人表皮生长因子受体2阳性转移性乳腺癌;成本-效用分析
Cost-utility analysis of pertuzumab combined with trastuzumab and docetaxel in first-line treatment of HER2-positive metastatic breast cancer
JIA Caifeng1,ZHANG Sen2,XU Hao3,LI Sainan4,WANG Mingxia1(1. Dept. of Clinical Pharmacology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 2. Dept. of Pharmacy, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 3. Dept. of Medical Insurance, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 4. Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China)
ABETRACT OBJECTIVE To evaluate the economics of pertuzumab combined with trastuzumab and docetaxel (PTD) regimen versus trastuzumab combined with docetaxel (TD) regimen in first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. METHODS From the perspective of Chinese healthcare system, the partitioned survival model was constructed by using survival data disclosed in the CLEOPATRA clinical trial and relevant literature data. The time horizon of the model was set as 20 years and the cycle length of the model was 3 weeks, and discount rate was 5%. The output indicators of the model included the cost and quality-adjusted life years (QALYs) of the two treatment regimens. The threshold of willingness-to-pay (WTP) was set as 1-3 times per capita gross domestic product (GDP) in China in 2020, i. e. 72 000-216 000 yuan/QALY. One-way sensitivity analysis and probabilistic sensitivity analysis were used to evaluate the influence of model parameter changes on the robustness of the results. RESULTS The results of base-case analysis showed that within the horizon of 20 years, PTD regimen could bring more health benefit than TD regimen (3.28 QALYs vs. 2.50 QALYs),but the total costs was higher (1 219 376.83 yuan vs. 784 007.84 yuan). Compared with TD regimen, the incremental cost-effectiveness ratio of PTD regimen was 554 625.46 yuan/QALY,which exceeded threshold of WTP. The results of one-way sensitivity analysis showed that the utility of progression-free survival state had the greatest impact on the results; the results of probability sensitivity analysis showed that the probability of PTD regimen considered as to be cost-effective was 1% when using the 3 times per capita GDP in China in 2020 as the threshold of WTP; when the threshold of WTP increased to 550 000 yuan/QALY, the probability of PTD regimen considered as to be cost-effective would reach to 50%. CONCLUSIONS Compared with TD regimen, PTD regimen is unlikely to be cost-effective in first-line treatment of HER2-positive metastatic breast cancer.
KEYWORDS pertuzumab; trastuzumab; docetaxel; human epidermal growth factor receptor 2-positive metastatic breast cancer; cost-utility analysis
据世界卫生组织国际癌症研究机构公布的2020年全球最新癌症疾病负担研究结果显示,乳腺癌已超越肺癌成为全球发病率最高的癌种,且已成为我国女性发病率最高的癌种,2020年我国新发病例数达42万[1]。……
